Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.

Maria Rosaria Valerio, Colangelo, De Vincenzo, Colangelo, Scambia, Tullia Prantera, Vanda Salutari, Gabriella Ferrandina, Domenica Lorusso, Giovanni Scambia, Ludovisi

Risultato della ricerca: Articlepeer review

26 Citazioni (Scopus)

Abstract

A prospective phase II study was conducted to evaluate the efficacyand toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12months. PATIENTS AND METHODS: DTX, 75 mg/m(2), was administered by 60 min i.v.infusion, followed by OXA, 100 mg/m(2), given by a 2 h i.v., on day 1 every 21days. RESULTS: From October 2003 to June 2006, 43 ovarian cancer patients wereenrolled. Median PFI was 26 months. All patients were available for responseevaluation: 17 complete responses and 12 partial responses were registered, foran overall response rate of 67.4%. The median response duration was 10 months.Stable disease was documented in 11 patients (median duration = 5.5 months). The median time to progression and overall survival were 14 and 28 months. A total of259 courses were administered. Grade 3-4 leukopenia was documented in 32.5% ofthe patients, while no case of severe anemia and thrombocytopenia was observed.Grade 3-4 neurotoxicity and grade 2 alopecia were observed in 9.3% and 34.9% ofcases, respectively. CONCLUSION: DTX/OXA combination is an active regimen with a favorable toxicity profile, for treatment of recurrent platinum-sensitive ovarian
Lingua originaleEnglish
pagine (da-a)1348-1353
Numero di pagine6
RivistaAnnals of Oncology
Volume18
Stato di pubblicazionePublished - 2007

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Entra nei temi di ricerca di 'Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.'. Insieme formano una fingerprint unica.

Cita questo